Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Leitersdorf

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Drugs|January 1, 1994
Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemiaE Leitersdorf
British Journal of Clinical Practice. Supplement|June 6, 2009
The patient at risk: who should we be treating?E Leitersdorf
International Journal of Clinical Practice|April 3, 2002
Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering managementE Leitersdorf
Current Opinion in Lipidology|April 1, 1994
Cerebrotendinous xanthomatosisE Leitersdorf, V Meiner
Cardiology|November 1, 1996
Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatmentI Shviro, E Leitersdorf
Genetic Epidemiology|January 1, 1995
Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemiaY Friedlander, E Leitersdorf
British Journal of Clinical Practice. Supplement|January 1, 1996
The patient at risk: who should we be treating?I Shviro, E Leitersdorf
Harefuah|August 1, 1992
[Lipoprotein (a)--a risk factor for atherosclerosis]V Meiner, E Leitersdorf
Harefuah|March 1, 1995
[Can regression of coronary atherosclerosis be induced?]O Caspi, E Leitersdorf
Harefuah|May 1, 1995
[Impact of hormone replacement therapy on the cardiovascular system]I Shviro, E Leitersdorf
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Drugs|January 1, 1994
Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemiaE Leitersdorf
British Journal of Clinical Practice. Supplement|June 6, 2009
The patient at risk: who should we be treating?E Leitersdorf
International Journal of Clinical Practice|April 3, 2002
Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering managementE Leitersdorf
Current Opinion in Lipidology|April 1, 1994
Cerebrotendinous xanthomatosisE Leitersdorf, V Meiner
Cardiology|November 1, 1996
Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatmentI Shviro, E Leitersdorf
Genetic Epidemiology|January 1, 1995
Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemiaY Friedlander, E Leitersdorf
British Journal of Clinical Practice. Supplement|January 1, 1996
The patient at risk: who should we be treating?I Shviro, E Leitersdorf
Harefuah|August 1, 1992
[Lipoprotein (a)--a risk factor for atherosclerosis]V Meiner, E Leitersdorf
Harefuah|March 1, 1995
[Can regression of coronary atherosclerosis be induced?]O Caspi, E Leitersdorf
Harefuah|May 1, 1995
[Impact of hormone replacement therapy on the cardiovascular system]I Shviro, E Leitersdorf
Pageof 11